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RA is a complex disease that develops as a series of events often referred to as disease continuum. RA would benefit from
novel biomarker development for diagnosis where new biomarkers are still needed (even if progresses have been made with the
inclusion of ACPA into the ACR/EULAR 2010 diagnostic criteria) and for prognostic notably in at risk of evolution patients with
autoantibody-positive arthralgia. Risk biomarkers for rapid evolution or cardiovascular complications are also highly desirable.
Monitoring biomarkers would be useful in predicting relapse. Finally, predictive biomarkers for therapy outcome would allow
tailoring therapy to the individual. Increasing numbers of cytokines have been involved in RA pathology. Many have the potential
as biomarkers in RA especially as their clinical utility is already established in other diseases and could be easily transferable to
rheumatology.We will review the current knowledge’s relation to cytokine used as biomarker in RA. However, given the complexity
and heterogeneous nature of RA, it is unlikely that a single cytokine may provide sufficient discrimination; therefore multiple
biomarker signatures may represent more realistic approach for the future of personalised medicine in RA.
1. Biomarker Research
1.1. General Features of Biomarkers. Biomarkers are defined
as anatomical, physiological, biochemical, molecular param-
eters or imaging features that can be used to refine diagnosis,
measure the progress of diseases, or predict and monitor the
effects of treatment. They can also be associated with the
severity of specific disease states.
Biomarkers can be detected and measured by a variety of
methods including physical examination, laboratory assays,
and medical imaging. Some biomarkers arepresent in partic-
ular groups of patients but not others, and as a result they are
defined as qualitative biomarkers in contrast to quantitative
biomarkers that are present at various degrees/levels in all
patients. The accessibility of a biological biomarker, which is
defined by themethods that are used to access the biomaterial
necessary tomeasure it, is an important factor in relation to its
adoption in clinical practice. If a biomarker can be obtained
in a minimally invasive manner (typically from blood, saliva,
or urine) or use tissue imaging as opposed to tissue sampling
(biopsy), it will obviously be more attractive.
In the context of rheumatic diseases, typical biological
biomarkers could encompass genetic markers, products of
gene expression, autoantibodies, cytokine/growth factors,
acute phase reactants, tissue abnormalities visualized by
immunohistochemistry in synovial biopsy, a product of tissue
degradation, or a cell subset that can be phenotyped and
enumerated. The sources of these biomarkers could be the
serum/plasma, urine, synovial fluid, tissue biopsy, or cells
from blood, fluid, lymph node, or tissue. In contrast, a
clinical biomarker (i.e., clinical surrogate) would constitute
a physical variable (sign or symptom), a clinical judgment,
or an outcome measurement that emerges as a sequel of the
underlying disease process. In rheumatology, this variable
may be not only joint counts, global assessment, pain score,
duration of morning stiffness, and other clinical variables but
also composite indices or functional, radiographic scores.
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1.2. Specificity and Sensitivity. Sensitivity and specificity are
statistical measures of the performance of biomarker using a
binary classification test.Thismeasures use used a categorical
classification of patients with respect to true and false posi-
tive/negative results.
Sensitivity relates to the biomarker’s ability to identify
positive results. It measures the proportion of individuals
which are correctly identified by the biomarker. Sensitivity
is different from positive predictive value (PPV, also called
precision), representing the proportion of actual positives in
the population being tested.
On the other hand, specificity relates to the ability of the
test to identify negative results. It measures the proportion of
people without the biomarker that are correctly not assigned
to the condition. Sensitivity may be affected in case of
a number of indeterminate test results. It is possible to
exclude these cases from analysis or, alternatively, to treat
them as false negatives (which gives the worst-case value for
sensitivity but also underestimates it), but such exclusions
should be stated when quoting sensitivity.
An optimal biomarker would aim to achieve 100% sen-
sitivity (i.e., predict all people with the condition) and 100%
specificity (i.e., not predict anyone from the control group).
For any biomarker, there is usually a trade-off between the
measures and their impact, setting acceptable limits and
allowing detection of false positive (lowering specificity), but
limiting false negative (increasing sensitivity).
Taking the example of anticitrullinated peptide antibod-
ies (ACPA) in RA, sensitivity is usually reported around 68%
and specificity is reported at 95% [1]. However, sensitivity
is highly dependent on the group of individuals tested and
values observed in established diseases that do not reflect the
general RA patients’ population or early disease. Indeed, in
patient with recent onset of symptoms, studies have shown
that sensitivity ismuch lower (ranging from35% to 50%) even
if specificity remains closer to 95% [2].
Multivariate markers are as follows: the concept of
biomarker algorithm or multivariate biomarkers has recently
been developed based on the observation that a single
biomarker is often insufficient to predict the outcome of
interest, when a combination of biomarkers is better at
achieving the prediction. It is usually observed that multi-
variate biomarkers perform better in replicate studies than
univariate biomarkers.
1.3. Need for Biomarkers in Rheumatoid Arthritis (RA). RA
is a complex disease that develops as a series of events often
referred to as disease continuum. Research into the preclin-
ical and early phases of RA recently reviewed these events
and categorised groups of individuals based on risk factors
[3]. According to this new terminology, healthy individuals
without RA are described as having potentially two main
types of risks: (i) a genetic risk, for example, if they carry the
shared epitope allele and (ii) an environmental risk if they
smoke.They, however, do not present any laboratory evidence
of symptoms or any signs of inflammatory arthritis. The first
phase of RA disease progression would then be a state in
which individuals develop features of systemic autoimmunity
that can be measured by laboratory investigations and are
known to be associatedwith RA (such asACPA) [3] andmore
recently with carbamylated protein [4, 5]. These individuals
still do not present any symptoms or signs of inflammatory
arthritis. A further stage is then defined by the appearance of
symptoms (such as arthralgia/morning stiffness), still with no
evidence of any clinical synovitis.These individuals can come
from both the genetic and environmental risk groups, from
the systemic immunity group, or from the general healthy
population. Finally, the last progression stage is represented
by the development of clinically apparent inflammatory
arthritis that may not yet fulfil the criteria for RA diagnosis
[6], and hence it is being termed undifferentiated arthritis but
is likely to evolve towards RA.
There are many situations in RA, which would benefit
from biomarker discovery, considering that biomarkers may
be broadly classified as diagnostic (detected when disease is
present), prognostic (associated with disease outcome), or
predictive markers (associated with drug response). Diag-
nosis is obviously an area where new biomarkers are still
essential as RA is a condition where diagnosis relies on signs
and symptoms even if recent progress has been made with
the inclusion of ACPA to the recently updated criteria [6].
However, in RA diagnosis, the performance of biomarkers
may greatly depend on the duration of symptoms at the time
of test, the current level of inflammation, and the amount of
destructive processes already undergone, as well as on the
type of tissue tested. Prognostic biomarkers which predict
the future course of the disease and provide information
regarding the outcome irrespective of therapy would be very
important in foreseeing the evolution of undifferentiated
arthritis towards RA or with respect to the severity of RA
which can be quite variable. Prognostic biomarker validation
is therefore relatively straightforward, as it is associated with
the disease and the patient and can be established (at least
in theory) using data from a series of patients treated with
standard treatment. The discovery of specific biomarkers for
poor prognosis would, for example, enable early intervention
and intensive treatment. Risk biomarkers for predicting
rapid evolution or cardiovascular complications, for example,
remain highly desirable. Monitoring biomarkers would be
useful in predicting relapse and candidates are available
using flow cytometry based cell subset phenotyping [7–
9]. Predictive biomarkers would separate an RA patients’
population with respect to their outcome in response to a
particular event taking place (i.e., particular therapy). They
are therefore present/absent prior to the outcome occurring
and have obvious applications with the greatest potential to
affect clinical practice by targeting drugs to relevant patient
subgroups. Biomarkers allowing the selection of an optimal
drug for a particular patient (acknowledging that certain
subset of patients respond better to certain drug than others)
may represent another essential step in patients screening
that would notably allow personalised medicine models to
be developed, tailoring therapy to the individual, shortening
time from onset to effective treatment, improving cost and
risk-benefit ratios of drugs, and ultimately achieving high
response rate with minimal toxicity [10]; however, in patients
with long-standing RA heterogeneity in disease presentation,
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there remains a major obstacle even when using biomaterial
as close to the disease site as synovial tissue [11].
There are several sources of tissue and body fluid that
can be considered for biomarker discovery programs in
RA. The suitability between the levels of invasiveness and
the benefit provided by the biomarkers is however to be
considered as well as the level of investigation patients would
be likely to accept. Diagnostic biomarkers, considering the
prevalence of the disease (1-2%), would need to use biological
material which is easily accessible and a method of collection
which would not impact on the progression of the disease.
Blood and urine therefore appear more suitable compared to
synovial tissue or fluid particularly at this early stage of the
disease where mostly small joints are involved. Later in the
disease continuum, tolerability for more invasive procedure
such as fluid aspiration or biopsy collection would provide
material reflecting the disease site more closely allowing
for individual variability to be taken into account for a
personalised medicine approach.
2. Cytokines as Biomarkers
2.1. Cytokine Classification. Cytokines are small proteins
which play important roles in cell signalling. They are
secreted by a variety of cellular sources acting either on the
cell producing them (autocrine) or on the surrounding cells
(paracrine). They are classified as proteins and sometimes
peptides and can also be glycosylated. Cytokines usually
circulate in very small amounts (picomolar 10−12M) and,
nonetheless, their concentration can increase up to 1,000-
fold when required. Cytokines have originally been identified
in the context of the immune system; however, it has now
been shown that they are produced by and influence the
behaviour of a variety of nonimmune cells. Cytokines are
often referred to as “growth factors” by associationwith one of
theirmost common effects, the induction of cell proliferation,
despite a wide spectrum of roles in survival, apoptosis,
differentiation, and functional activation (contribution to the
immune response).
Over the years, cytokines have been categorized into
various classes, families, or superfamilies. It has been done
using either their numerical order of discovery (notably, in
the interleukin family, currently up to IL-38) or a given
functional activity (e.g., the larger tumour necrosis factor
family). In that case, they are further divided between
cytokines which enhance cellular immune responses (type 1)
as opposed to thosewhich favour antibody responses (type 2).
This subclassification is performed using their function (early
or late, innate or adaptive, pro- or anti-inflammatory, mito-
genic, regulatory, survival functions) or, sometimes, using
their primary cell of origin (monokine, lymphokine). More
recently, classification has been achieved using structural
homologies shared between related molecules. Nevertheless,
despite sharing sequence homology and some promiscuity
between their receptor systems, cytokines demonstrate speci-
ficity in their function and even opposing functions within
members of the same family (best illustrated in the TNF
superfamily).
Methods of detection for cytokines also vary consider-
ably. Enzyme-linked immunosorbent assays (ELISAs) have
long been considered the “gold standard,” but, nowadays,
the development of multiplexing technology has allowed
biomarker programs to investigate whole cytokine networks
as opposed to individual candidates notably enabling large
data sets to be generated from small body fluid volumes. Sev-
eral multiplexing technologies are now available, including
the bead-based immunoassay (often referred to as Luminex
assay), membrane-based ELISAs, andMosaic ELISAs, as well
as cytometric bead arrays (CBAs). Concerns have been raised
related to the sensitivity of somemultiplex solid-phase assays
[12] as well as interference from heterophilic antibodies [12–
19]. This is of particular relevance in autoimmune disease
where rheumatoid factor (RF), a heterophilic autoantibody
directed against the Fc portion of IgG is present notably in
RA [12, 20–25].
2.2. Variability and Limitations of Cytokine Measurements
2.2.1. Patient Related Variability. There are a number of fea-
tures and conditions that can influence cytokine production
which are related to donor variability in both health and
disease. Some of these characteristics are unlikely to change
during treatment (genetic/ethnic background, gender, and
age); however, others may greatly limit the ability to use
cytokines as biomarkers in everyday practice. These factors
such as diurnal rhythmicity and sample handling factors
(collection methods, storage, and plasma versus serum) may
influence the measurement of cytokines and are also likely
to change with not only therapy but also stress and cachexia.
Such factors are likely to contribute considerably to the
disparities seen among similar types of clinical studies [53–
55].
(1) Age and Gender Effects. Comprehensive analysis of 30
different biomarkers in ≈400 healthy donors, ranging in age
from 40 to 80 years, showed an increase in serum interferon-
inducible chemokines (MIG and IP-10), eotaxin, and soluble
TNFR-II with advancing age [56]. Multiple studies discussed
differences in cytokine production associated with donor age,
and several reports have demonstrated that chronic, low-
grade inflammation is linked with the aging process [57–
59]. An age-related increase in IL-6 concentration has been
reported in serum, plasma, and supernatants of mononuclear
cell cultures obtained from elderly subjects [60, 61]. Some
studies demonstrated that plasma levels of tumor necrosis
factor (TNF) are elevated in elderly populations [59, 62–
64]. Conversely, other cytokines regulating T cell functions,
such as IL-2, may be decreased with aging. The suppressed
production of IL-2 leads to a small clonal expansion of T
cells thus decreasing the ability to develop specific immune
responses [61]. Modifications of the immune system are glob-
ally evaluated as a form of deterioration called immunose-
nescence. However, ageing is also accompanied by a chronic
low-grade inflammation state, showed by a 2 to 4-fold
increase in serum levels of inflammatory mediators which
act as predictors of mortality independently of preexisting
morbidity. This proinflammatory status underlies biological
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mechanisms responsible for decline in physical function, and
inflammatory age-related diseases are initiated or worsened
by systemic inflammation [65].The term “inflammaging” has
been coined to explain the underlying changes common to
the most age-associated conditions [66, 67].
Longitudinal cytokine production in paediatric and adult
patients identified multiple differences in terms of proin-
flammatory cytokines such as IL-6, IL-8, IL-1alpha, IL-1beta,
MCP-1, MIP-1alpha, IL-15, IL-5, IL-17, IL-18, and IP-10 and
of anti-inflammatory cytokines such as IL-10, G-CSF, IL-
13, IFN-gamma, and IL-4 between the two groups [68].
Altogether, the age of onset in RA patients is to be taken into
consideration as it may reflect the cytokine production pro-
file. Men and women also present with gender related differ-
ences in the way their immune system responds to challenge
[69]. Females demonstrate better B cell-mediated immunity
than age-matchedmales (with higher immunoglobulin levels,
stronger antibody responses, and increased resistance to
certain infections). Gender also influences T cell immunity,
females having greater resistance to induced tolerance, an
increased risk to reject grafts, and higher levels of IL-1, IL-4,
and IFN-gamma in contrast to men who produce more IL-2,
-4, and -13 and whose monocytes secrete more IL-1beta and
TNF-alpha [70]. Differences in cytokine production profile
have also been suggested to play an important role in the
gender bias with regards to the ratio of relapsing remitting
and secondary progressive multiple sclerosis [71] as well as
susceptibility to urinary infection [72]. Aging has also been
associated with alterations of the musculoskeletal system
and a decline in sex hormone levels, which have a central
role in the regulation of bone turnover. The effect of age
combined with gender on cytokines and markers of bone
metabolism production showed an increased proportion of T
cells producing IFN-gamma and IL-2, IL-4, IL-10, and IL-13
particularly in elderly women after menopause [73].
(2) Circadian Rhythm. Cytokines present a circadian pattern.
For example, IFN-gamma, TNF-alpha, IL-1, and IL-12 pro-
duction exhibits distinct diurnal rhythms that peak in the
early morning [74] and are related to the rhythm of plasma
cortisol and melatonin [75–77]. Taking IL-6 as an example,
notably with respect to RA, IL-6 demonstrates important
variation in serum or plasma levels in healthy subjects over a
day period with a particular biphasic rhythm [78] altogether
amounting up to a CV >23%. After correction for analytical
variation, a rise in serum IL-6 in the late evening and the
earlymorning has been reported inRA [78–82] aswell as high
variations between andwithin days not necessarily indicating
rhythmicity [54]. Therefore, only IL-6 changes over twice the
biological variation (>50% difference) should be considered
significant [78]; however, in order to obtain comparable and
meaningful results, the time of sample collection should be
synchronized, with a morning sample collection time being
ideal. This does not affect all cytokines but is not particularly
well described for many and should be considered if/when
validating a biomarker for clinical use.
(3) Food Intake. Long-term food intake patterns (i.e., obesity
or weight loss) have been shown to affect circulating cytokine
levels, notably TNF-alpha [83]. Postprandial cytokine levels
are also affected by feeding; notably circulating IL-6 levels
are increased, while TNF-alpha levels are decreased [84–
87]. Food supplements (in particular, antioxidants such as
glutathione and vitamins E and C) can attenuate the feeding-
induced rise in plasma cytokines [88, 89]. Hence, patients
should be instructed to maintain normal dietary habits and
avoid food supplements prior to sample collection if the
cytokine of interest is sensitive to such regulation [90, 91].
(4) Exercise. Physical exercise can affect cytokine levels in the
circulation [54, 92]. While plasma cytokines are produced by
many cell types, muscle cells are a major source of secreted
cytokines during exercise [93, 94]. However, these particular
responses are highly specific to the exercise protocol and
physiological strain (duration, nature of the exercise, and
intensity) [95, 96]. Several studies reported elevation of
plasma IL-6 in healthy subjects, which peaked at the end
of exercise. The magnitude of the IL-6 response was related
to the duration and intensity of the muscle work, the mass
of muscle recruited, and the subject’s endurance capacity
[78, 97–99]. In patients with RA, no changes in serum IL-
6 were found after cycling. This could be due to the less
strenuous exercise performed by the RA patients because of
their widespread joint pain [78, 100]. In contrast, evidence
suggests that the prophylactic effect of prolonged, endurance
type exercise protocols may be mediated via the induction of
an anti-inflammatory environment (increases in circulating
levels of IL-1RA and IL-10) [101]; however, how/whether
both are linked remains poorly defined.There is nevertheless
consensus that exercise training protects against some types
of cancers by enhancing antitumour immunity and reducing
inflammatory mediators. Altogether, any unconventional
strenuous activity prior to blood collection for cytokine
measurements should be avoided.
(5) Stress. Stress and emotional problems were also shown
to influence cytokines levels; however, studies yielded con-
tradictory data with decrease, increase, and no change in
proinflammatory cytokine production being reported [102–
104].Nevertheless, lower self-rated healthwas associatedwith
higher levels of inflammatory cytokines IL-1 and TNF-alpha
(controlling for age, education, and physical health) [104].
2.2.2. Preanalytical Related Variability. There are several
specific problems posed by sampling conditions (i.e., preana-
lytical issues) in addition to those described above. Cytokines
act either in a paracrine or an autocrine manner as they are
released and consumed locally, close to the site where the
immune reaction occurs.Therefore, they are rarely detectable
in peripheral blood and then only at low levels [105]. Blood
may thus only partly reflect pathologies, including RA, and
therefore not be the material of choice. The half-life of many
cytokines is also measured in minutes; hence, the time lapse
between the collection andprocessing of the samplesmay be a
significant factor limiting the use of cytokines as biomarkers.
Data reproducibility can be affected by normal human
variability, which is relatively easy to control inmodel systems
(i.e., in cell culture or even animal models) but is much
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harder to control in real subjects. Designing and testing
the sample collection (i.e., anticoagulants, stabilizing agents)
and handling (temperature, elapsed time from collection to
initial processing, and endogenous degrading properties of
the analyte) and processing protocol/method will represent
key elements in the successful development of any biomarkers
[106].
(1) Serum or Plasma? In body fluids, cytokines can exist under
multiple molecular forms related to posttranslational modifi-
cations (i.e., glycosylation), monomers/polymers, precursors,
and degradation products or complexed with other proteins
[107]. Such molecular forms can behave differently in assays
used to determine their levels; therefore, choice of different
analytical techniques will be determinant in selecting blood
preparation. Serum and plasma are not interchangeable,
and the use of one or the other will determine which
technique should be used for analyte quantification (see
Table 1). Therefore, a lack of consensus exists with respect to
the optimal type of specimen to measure cytokines, and the
question remains open as to whether plasma or serum should
be used. It is important to determine if the method used to
collect and prepare the sample may introduce alterations to
the cytokine to be tested (i.e., cytokines, either individually or
on all proteins in the sample) or whether certain preparation
methods are desirable or not for certain cytokines [108].
Serum represents the soluble fraction of clotted blood.
Serum preparation involves the removal of fibrinogen,
platelets, and other circulating proteins. Clotting takes a
minimum of 30 minutes but no longer than 60 minutes.
Blood should then be centrifuged for 10 minutes and serum
should be separated from the clot. Blood cells may get
activated during the clot formation and cytokines may be
released as a result (such as IL-1, IL-6, and CXCL8) [27, 90,
109, 110]. Rapid sample processing is therefore essential to
accurately measure cytokines due to platelet release (i.e., IL-1,
IL-6, sCD40L, and others) [21]. For this reason, in order to
have correct estimates of specific cytokine levels, it may be
preferable to measure them in plasma rather than in serum
[34, 111]. This notably raised issues when comparing serum
and plasma levels for TGF, IL-1, IL-6, IL-7, and so forth [38].
Plasma is the soluble fraction of anticoagulated blood. To
obtain plasma, various anticoagulants can be used (ethylene-
diaminetetraacetic acid (EDTA), lithium/sodium heparin,
and sodium citrate). Cytokine measurements were shown
to be affected by the anticoagulant used [78] and, notably,
lithium heparin and sodium citrate were shown to affect
levels of IL-6 and TNF-alpha compared to EDTA plasma [35,
112, 113]. Citrate plasma collection also results in the reduction
of total protein concentration due to the volume of citrate
anticoagulant diluting the blood, in addition to an osmotic
withdrawal of water from blood cells [114]. Endotoxin present
in lithiumheparin tubeswhen sterility is broken [113] can also
induce cytokine release from cells, whereas EDTA inhibits
endotoxin [26, 31]. Variation in cytokine levels could be
attributed to anticoagulant-induced release of cytokines by
blood cells notably in heparin plasma but not in EDTA
plasma, [115]. Altogether, plasma collectionwith use of EDTA
seems to bring the most consistent results [34, 35, 116] and
more closely resembles data obtained in serum [31, 35, 39, 78,
90, 117]. Cytokine stability also appears increased in EDTA
plasma [26, 118] perhaps through EDTA’s role as a protease
inhibitor. Further mechanisms can explain differences in
stability such as change in degradation rate or modification
of cytokine’s structure due to the differential presence of
other proteins in EDTA plasma compared to citrate plasma
or serum (i.e., soluble forms of receptors) leading to a
lack of recognition of the antibodies used in the ELISA.
The limitation in using plasma remains the need for rapid
separation after collection with changes occurring as soon as
30 minutes after sample collection [34].
Over the recent years, improvements in the collection
tubes have been made, notably with the use of serum
separator tubes, which include a gel that serves as a barrier
between serum and the clot [106], or the substitution of
plastic for glass allowing direct centrifugation [119].
Altogether, no single type of sample is optimal for every
analyte; therefore, the development of assays for individual
cytokines should require optimisation on a case-by-case
basis, although it would be recommended to collect both
serum and EDTA plasma.
(2) Time to Processing. Time is an important factor that needs
to be accounted for when measuring circulating cytokines
which have a relatively short half-life and an important risk of
degradation notably when comparing them to other proteins
such as antibodies [26, 34, 120]. Changes in the amount
of cytokine detected depend on the delay and duration of
sample processing and are likely due to altered production
by cells after blood collection [31, 54, 120], or their binding
by other proteins (i.e., soluble receptors or cells surface
receptor) [42, 120, 121], or, finally, due to enzymatic activities
(proteases) leading to cytokine digestion (see also Table 1).
Rapid processing of samples is therefore essential, notably
as samples obtained from patients often present with higher
concentrations or increased activity of proteases or other
factors which render specimens even more unstable than
those obtained from healthy controls [111]. Ideally, samples
destined for cytokine detection should be collected in sterile
(endotoxin-free) tubes and processed quickly with a mini-
mum of 30 minutes of clotting time but no longer than 60
minutes after blood draw, independently of the type of tube
used (plasma or serum). Processed plasma or serum should
be frozen at −80∘C as soon as possible in small aliquots to
avoid repeated freeze-thaw cycles [107, 122]. Some reports
proposed to keep samples refrigerated at 4–8∘C (but not on
ice) after clotting for the duration of processing as room
temperature favours proinflammatory cytokine degradation
such as IL-6 but conversely stabilises TNF-alpha [26, 34,
120, 123, 124]. Most cytokines are relatively stable with the
well-known exception of TNF-alpha and IL-6 [42, 125, 126];
therefore, the interval between blood draw and separation
should not exceed 3–24 hours, even when the tubes are stored
at 4–8∘C and only when EDTA tubes are used (TNF-alpha
however cannot be reliably measured any longer), although
many cytokines have not been sufficiently tested [26, 35, 37,
78].
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The effects of centrifugation speed are more difficult to
evaluate. Gradual increase in g values (from 200 to 13,000 g)
is necessary to achieve graded depletion of platelets and
leucocytes from plasma; however, it reduces the levels of
certain cytokines (i.e., sCD40L) [52]. Of note, the use of blood
tubes with gel separator imposes a certain centrifugation
speed to allow separation of serum and cells but does not
allow tubes to be chilled before or during centrifugation [127].
(3) Storage Temperature and Freeze-Thaw Cycles. By and
large, most cytokines and soluble markers are quite stable
if frozen (see also Table 1). Storage conditions, however,
vary with a choice of temperatures from short-term storage
at room temperature (RT) or 4–8∘C (days) to medium
term (a few months) more often between −20/−30∘C and
long term (years) at −70∘C. Direct comparison of several
cytokines in plasma stored for 20 days at RT, 4∘C or −70∘C,
showed remarkably stable levels (IL-10) except for TNF-alpha
particularly at room temperature [128]. In contrast, a more
recent study of reliability and reproducibility of cytokine
measurements in healthy donors [122] showed that, while
most cytokine measurements are stable for up to 2 or 3 years
when stored at −80∘C (see details in Table 1), they do not
all remain stable after repeated freeze-thaw cycles. After 4
years, most cytokines were degraded. Importantly in RA,
levels of certain cytokines such as TNF-alpha increase with
each successive freeze-thaw cycle [54, 90, 122]. Therefore, it
remained difficult to compare studies from different centres
even when using the same assay for cytokine measurements
(i.e., commercial kit) [39]. Altogether, the consensus would
recommend storing specimens at −80∘C in as many small
aliquots as possible to limit freeze-thaw cycles [129].
2.2.3. Analytical Variability
(1) Assay Type. Numerous immunoassays exist to measure
cytokines both in their protein form: ELISA, nitrocellulose, or
other solid phase assays, immunohistochemistry, and bead-
based flow cytometry multiplex immunoassays, and in their
molecular form: reverse transcriptase PCR, microarrays, and
in situ hybridisation (Table 2). Immunoassays use antibody
to immobilise cytokines on a solid surface and then identify
them with different methods for quantification using colori-
metric enzymatic reactions, fluorescence, luminescence, or
even, in the past, radioactivity. There are two types of assays
using either one or two antibodies: one being for cytokine
capture adding more specificity compared to total protein
plastic binding and the second one being for detection.
The major benefit to using antibodies is that assays are
more specific and reproducible. Several platforms for the
detection and quantification of cytokines exist. There is no
universal best method for cytokine measurements; however,
the oldest technique (ELISA) is often used as gold standard
despite the fact that direct comparison between many com-
mercially available kits has not been performed. Cytokines
show complex protein structures (monomers/polymers, pre-
cursors, various degrees of glycosylation, and degradation
products) and their activity often depends on the integrity
of such structure. Minor changes that may not be detected
by physicochemical measurements, immunoassays, or bio-
physical methods may have dramatic effects on biological
activity (e.g., cytokines may lose most of their biological
activity but will remain detectable if measured as mass)
[130].The presence of soluble forms of the cytokine receptors
(i.e., sIL-2R, sIL-7R, and sTNF-R) in biological samples and
the existence of autoantibodies to cytokines (i.e., anti-TNF-
alpha, IL-6, and IL-1) [131] may or may not interfere with
the recognition of cytokines by either capture or detection
of antibodies [39, 132–134]. Each method has advantages and
limitations and should be carefully selected with respect to
the research purpose. To date, most cytokine measurements
in large studies essentially used ELISA, which is widely
accepted as the “gold standard” method. The main limitation
of ELISA remains that it allows the characterization of a
single cytokine at a time, hence the development of multiplex
technologies. One of the most commonly used methods
for this is the multiple target based assay [135], which can
measure up to 100 different analytes per sample from a small
volume of body fluid [136], or more recently the cytometry
bead assay (CBA) which relies on bead as solid phase
and uses flow cytometry to discriminate between analytes
[137]. Multiplex measurement of inflammatory cytokines
in human serum by electrochemiluminescence assay was
recently developed [138]. These multiplex assays are in con-
cept close to ELISAs and dependent upon the careful choice
of the capture/detection antibody pairs and proper buffering
to minimize differences in assay performances [135].
Several studies have compared cytokine levels deter-
mined by ELISA and multiplex immunoassays with results
showing either good or poor correlations between the meth-
ods. Therefore, it is not surprising that discrepancies in data
comparing measurements of cytokines were observed when
different commercial/manufacturers’ kits were used, even if
preanalytical conditions of samples collection, separation,
and storage were identical [85, 136, 139]. The use of different
antibody clones to capture and detect cytokines is also likely
to affect results and change the level of sensitivity of such
assays. Furthermore, some monoclonal antibodies recog-
nise different molecular complexes (monomers/polymers,
precursors, glycosylation, degradation products, or total
bioactive or inactive forms) [140]. In summary, comparison
of the same samples (eliminating preanalytical bias) using
several commercial ELISAs demonstrated that variability was
mostly attributable to each assay (measuring TNF-alpha, IL-1
alpha and IL-1beta, IL-6, IL-2, IFN-gamma, and the soluble
receptors of IL-2 and TNF) but yielded comparable results
when the same ELISA was used at different centres [85, 139].
The nature of the different pairs of monoclonal antibodies
employed in each ELISA is most likely the major source of
variability, but these findings also highlight the necessity of
establishing international standards for all immunoassays as
ranges are also widely variable between these commercial
assays. If cytokines are to be employed as clinical biomarkers
for diagnosis, prognosis, and prediction, accurate and repro-
ducible assays need to be adopted internationally.
(2) Interferences. Interferences within immunoassays are
numerous, complex, and usually difficult to resolve. Proteins
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Table 2: Description and characteristics of assays measuring cytokines.
Cytokine assay
technique Description Characteristics
Bioassays
Bioassays (commonly used shorthand for biological
assays) are typically assays by which the potency or the
nature of a substance is estimated by studying its effects
on living organisms
They can be conducted to measure the
concentration/effects of a cytokine on a living cell
Example: IL-2 bioassay using an IL-2 dependent cell
line that will undergo apoptosis in the absence of IL-2
in a dose dependent manner
They require tissue culture facility
Low specificity
Semiquantitative detection
Highly sensitive with detection limit < 1 pg/mL
Narrow analytical range
Time consuming (24–96 h)
Low precision (CV = 20–100%)
Drug interference
Laborious protocol with high staff cost
ELISA
Quantitative detection of a molecule (bioactive and
inactive) based on its capture by an antibody followed
by its detection by another antibody coupled with a
detection (commonly named ELISA)
It requires specialised equipment
Less sensitive than bioassays <10 pg/mL
Relatively large sample volume
Wide analytical range
High reagent cost
Excellent precision (CV = 5–10%)
No drug interference
Simple and relative rapid protocol
Solid phase assay
(Luminex)
Technology based on the detection of dyed microbeads
capturing a cytokine with a first antibody and
quantifying it with a second antibody coupled with
fluorescence and lasers detection
It allows multiplex detection
Small sample volume
Lower sensitivity than ELISA
Large range of analytes
Sensitive to interferences from heterophilic
antibodies (i.e., naturally occurring anti-antibodies),
anti-cytokine antibodies, and presence of soluble
receptors
Other solid phase
assays
Mosaic ELISA
ELISA like technology allowing multiple detection of
cytokines in a 96-well plate format by spotting capture
antibodies
Small sample volume
Lower sensitivity than ELISA
Only 8 analytes per test
Molecular techniques
All techniques allowing mRNA quantification
Earlier detection of cytokines at transcriptional level
however may not represent cytokine production and
release
They require specialised equipment
Highly specific
Highly sensitive as they can detect changes at the
single-cell level
Complete analytical range (from single cytokine to
as many as needed)
Excellent precision
No drug interference
Simple and relative rapid protocol
Relatively high cost
can show an altered expression pattern in more than one
disease.The presence of lipids, complement factors, and other
complex molecules in the blood was also shown to interfere
with a number of assays. Human anti-animal antibodies
present in biological samples (especially human anti-mouse
antibodies) may cause problems; however, these may be
blocked by the use of multiple species serums as blocking
agents [141]. Haemolysis interference occurs rarely; however,
it can affect some analytes. Lipaemia interferences were
confined when using immunonephelometric and immuno-
turbidimetric assays, and, ideally, grossly lipaemic samples
should be cleared (using ultracentrifugation of lipaemic
samples with correction for volume displacement errors) or
discarded. Antigen excess may, in some cases, result in false
low values [142]. Complement factors and paraproteins are
capable of binding to assay antibodies (capture and detection)
causing interferences [142]. In addition, biological fluids may
also contain naturally occurring antibodies to a variety of
proteins, including cytokines themselves. Such antibodies,
although at variable levels notably between normal donor
and patient populations, can interfere with assays particu-
larly if they share the same epitope on the cytokine [143].
The existence of autoantibodies against cytokines has been
documented for TNF, IL-1 (alpha and beta), IL-2, IL-6, IL-
8, IL-10, and IL-18 [144–148]. Autoantibodies against IL-1 are
the best studied. Their prevalence is high with an affinity
which can reach up to 10−11M that is very similar to the
affinity of antibodies developed for immunoassays [140].
However, the main issue remains heterophilic antibodies.
These antibodies are naturally produced polyclonal autoan-
tibodies with low specificity directed against multiple poorly
defined antigenic immunogens. Most often, they are present
in individuals exposed to foreign proteins (e.g., domestic ani-
mals and household pets). The occurrence of false positives
in immunoassays [13–16] is often the result of heterophilic
antibodies nonspecifically bridging the assay antibodies [18,
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19]. As a result, studies have often overestimated cytokine
levels notably when using the Luminex technology [12].
Blood samples from patients with autoimmune diseases,
such as RA, may be problematic due to the presence of
additional disease related autoantibodies [149]. RF is an
autoantibody directed against the Fc portion of IgG and is
found in 75% of patients presenting with RA as well as other
diseases such as Sjo¨gren’s syndrome, infective endocarditis,
systemic sclerosis, and systemic lupus erythematous (SLE)
[24]. RF was shown to exhibit most of the heterophilic
antibody properties with several antigen cross-reactions [25]
and hence immunoassay in RA is particularly sensitive to this
issue and needs careful evaluation for RF interference [12,
150–153]. Heterophilic immunoglobulin may further develop
as a result of treatment with drugs attached to mouse (or
humanised) monoclonal antibodies.
Several methods for removing heterophilic antibody
(notably RF) frompatients sera have been developed [21, 154–
156]: (i) initial serial dilutions may be recommended, partic-
ularly when results demonstrate nonlinearity suggesting the
presence of heterophilic antibodies, (ii) the use of blocking
reagents such as nonimmune serum from the same species
as the assay antibodies, species-specific polyclonal IgG, and
multispecies mixture (20% normal mouse serum, 10% goat
serum, and 10% rabbit serum), as well as commercial reagents
such as HeteroBlock [155], and (iii) the specific removal
of immunoglobulin G using sepharose-L or polyethylene
glycol precipitation (PEG 6000) has also been used. These
methods act by physical removal of the immunocomplexes
[155], which are then separated by centrifugation. Several
reports have been published investigating interference by
heterophilic antibodies in RA sera using solid phase mul-
tiplexing technology including Luminex [23, 155, 157, 158],
a glass chip/chemiluminescence platform, or a multiplex
sandwich ELISA. They showed clear interference (i.e., false
positive) in RF-positive sera but not in negative samples [157].
In our lab, all methods were efficient at blocking/removing
relatively low RF quantities in serum samples from RA
patients [12]; however, none of these methods were effective
when high levels of RF were present (>100 U/L) and residual
RF still generated false positive results particularly when
using certain types of assays (Luminex) but not others
(ELISA, membrane-based ELISA, Mosaic ELISA, or CBA).
(3) Standardisation and Quality Control. Commercially avail-
able immunoassays in the form of “kits” are now extensively
used. Considerable variability can arise from the use of
these assays. Differences in measured levels of cytokines in
identical samples using different standards ranged from 10-
to 100-fold [130, 159–161]. Some issues are related to the
use of different epitope specificity of the antibodies, while
others arise due to the use of various reference preparations
(standards) for calibrating the assays [55]. Comparison of
cytokine levels requires unit definition by a standard that is
assay independent, which, once defined, should be used by
any laboratory, thus providing a means of ensuring unifor-
mity worldwide [130]. Variations as a result of differences
in standards account for as much variability as sample
collection, processing, or storage issues [31, 42, 125, 159–168].
All cytokine assays should therefore be calibrated against
such standards, regardless of assurances provided by the kit
manufacturers. Notably, results of cytokine assays should be
reported in picograms or nanograms per milliliter instead
of arbitrary units. Major international efforts to organise
standardisation of cytokine measurements have been con-
ducted by the World Health Organisation, (see details at
http://www.nibsc.ac.uk/products/biological reference mate-
rials.aspx), The National Institute for Biological Standards
and Control (NIBSC), and the Biologics Evaluation and
Research (TheNational Institutes of Health (NIH), Bethesda,
MD 20205, USA) (http://www.who.int/biologicals/) [130, 131,
169]. Nonetheless, baseline values for a lot of cytokines have
not yet been reliably established in healthy controls (despite
a range suggested bymost manufacturers), making it difficult
to interpret the biological significance of minor variations in
cytokine levels in patients [170]. Furthermore, some cytokine
assays are sensitive at relatively high concentrations that may
not always cover the physiological range even in diseases
[12]. Quality control (QC) measure is also an essential step
of biomarker development. Therefore, during the analytical
phase, QC should be considered to document analytical
performance during any studies to determine the acceptance
or rejection of an analytical run during postanalytical sample
analysis [136, 171]. QC samples could be prepared to evaluate
the lower, middle, and upper performance limits of an
assay. A number of validation samples (at least five different
concentrations) should also be used to estimate intra- and
interrun accuracy/precision and stability [136, 172, 173].
3. Cytokines Network in RA
Over the years, increasing numbers of cytokines have been
involved in RA pathology, further to those used as target
of cytokine-blocking therapies which emerged from the
hypothesis that the most abundant cytokines present in
the joint were more likely to be pathogenic. A large num-
ber of cytokines are detected at the disease site (through
both mRNA and protein quantification) in both synovial
tissue and fluid, where they have a role in perpetuating
inflammation, cartilage destruction, and bone remodelling
associated with RA. Several methods of detection (ELISA,
immunohistochemistry) identified TNF-alpha and IL-1 as
major players in the network of cytokines, notably directly
expressed at the disease site in joint tissue or fluid. IL-6 and
IFN-gamma are also present as well as GM-CSF and LIF.
More recently, other cytokines were added to this list (IL-7,
IL-15, IL-17, IL-18, IL-21, and MIP-1 notably) together with
cytokines with activities targeted towards fibroblasts (TGF-
betas notably) and finally several growth factors (PDGF, EGF,
and VEGF) [174] and chemokines (IL-8, SDF-1, RANTES,
andMCP-1). Cytokines favouring survival of infiltrating cells
have also been detected (such as the pairs between IL-7 and
T cell or BAFF and B cells). However, if proinflammatory
cytokines (TNF-alpha, IL-1, and IL-6) are abundant in all
patients, cytokines classically defined as anti-inflammatory
and regulatory (IL-4, IL-10, IL-13, and TGF) [175, 176] as well
as antagonist receptors (IL-1RA, or soluble IL-2R, or TNF-R)
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are also present. Most of these cytokines have dual roles with
anti- and proinflammatory aspects depending on the context
and the network they form; hence, studying their roles
and actual effects is particularly complex. The redundancy
and synergy between the effects of all cytokines in such
an intricate network may further explain the inadequate
response to single blockade therapy notably in established
disease [175].
The interplay between cytokines, where excess of one
may result in suppressed production of another, further
complicated by interactions with soluble receptors for some
of these cytokines, renders data interpretation challenging
(notably for TNF-alpha and IL-1) [88, 89]. The relationship
between blood and tissue is often complex and translating
findings often proves difficult if not conflicting. Data on
cytokine levels in humans in relation to disease activity
is still limited. Increased levels of cytokines such as IL-
l, IL-6, and TNF have been interpreted as an indicator of
the inflammatory state. It is unlikely that these cytokines
could serve as “biomarkers” in inflammatory disease, as they
are linked to the disease biological processes, hence not
specifically associated with a particular disease. Additionally,
lack of correlation is often observed between cytokine levels
(in serum/plasma) and clinical endpoints.
On the other hand, the absence of a cytokine in disease
is particularly difficult to interpret. As indicated above, there
may be multiple reasons for the inability to detect a cytokine
when actually it is expected to be found. Even in the absence
of specific or nonspecific inhibitors, excessive consumption of
a cytokine versus lack of its synthesis is hard to dissociate. As
an example, IL-7 levels were reported to be low in RA serum
[177–179]; however, they are high in synovial fluid and tissue.
The presence of high levels of sIL-7R in serum [180] may
explain this discrepancy and the associated loss of biological
activity [177, 181].
Despite these limitations, there are some cytokine
biomarkers, which appear to be relevant in RA. IL-6, despite
not being disease specific [78, 92, 182], was shown to be more
sensitive than CRP (despite being directly correlated with it)
for the prediction of therapeutic response of RA patients to
rituximab [183]. Similarly, IL-7 was shown to have some value
as diagnostic biomarker associated with potential for more
erosive disease [179].
3.1. Differential Cytokine Expression between Diseases. Over
the years, many studies provided evidence of differen-
tial expression of cytokines between healthy control (HC)
and diseases such as RA, osteoarthritis (OA), ankylosing
spondylitis (AS), psoriatic arthritis (PsA), reactive arthritis
(ReA), systemic lupus erythematosus (SLE), or gout. These
initially used functional assays measuring the production of
cytokines in variable cell subsets using intracellular expres-
sion of cytokines (in CD4+ or CD8+, T cells or B cells,
or monocytes), ELISA, ELISOPT, or mRNA quantification.
Several important observations were derived from these
experiments and the tables below summarise all this data as
well as tissue sources and technology/experiment.
In vitro assays removed the microenvironment context;
however, they reflect good the capabilities acquired through
exposure to the priming effect that such microenvironment
may exert (i.e., Th1/Th2 polarization, transition from naı¨ve
to memory). Altogether, they demonstrate the dysregulated
expression of certain cytokines in T cells subsets notably
and increased expression by monocytes in RA patients.
Importantly, all cytokines tested were shown to be increased,
with the exception of IL-2 and IL-4. Interestingly, RApatients’
T cells showedhyporesponsiveness to stimulation of theT cell
receptor (TCR) pathways and hardly produced any cytokines
despite evidence of previous activation (memory phenotype)
[184]. This deficit was attributed to chronic exposure to
TNF-alpha [185] and/or abnormal RAP1 signalling [186–188].
The classic model of T cell naı¨ve/memory differentiation is
perturbed in RA. T cells despite being na¨ıve with respect to
antigen stimulation [189] express chemokine receptors which
facilitate trafficking to sites of inflammation [7, 177].This phe-
nomenonwas hypothesized to result fromcytokine activation
notably of na¨ıve T cells (by IL-6 and TNF-alpha) bypassing
the need for an antigen to achieve activation [190, 191]. Similar
cells were found in RA joint (but not OA) [192] where they
enable TNF-alpha production by monocytes in an antigen-
independent manner. These properties of cytokine activated
T cells were further extended to chemokine production and
were confirmed in vivo using a cytokine cocktail containing
IL-2, IL-6, and TNF-alpha [193]. Such increased ability to
produce all types of cytokines reflects the chronic stage
of the disease but nevertheless gives insight into potential
candidates for further biomarker program.
3.2. Differential Cytokine Levels in RA Sera or SF. There are
several studies comparing circulating levels of cytokine, they
often show discrepancy in their results, and most do not
use the appropriate biomarker development strategy. IL-1beta
and TNF-alpha are increased in RA [194] and such profile is
accentuated in active diseases compared to clinical remission
[195]. In contrast, low levels of IL-2 and IL-7 were reported
[177, 179, 194, 196]; however, those may be due to high
levels of soluble sIL-2R and sIL-7R which are also present.
IL-6 could not be detected in HC serum, while serum IL-
6 levels are substantially increased in RA with significant
circadian variations corresponding to the circadian rhythm
of symptoms in RA [79]. High IL-7 [197] and IL-16 [198]
were detected in sera and SF of RA patients compared to OA
and are also confirmed in synovial tissues by mRNA levels.
Certain cytokine levels were related to disease parameters
such as IL-1RA and the number of tender and swollen joints
[199], IL-18 (both sera and SF) and disease activity [200, 201],
and IL-7 in the tissue (both mRNA and protein) with local
levels of inflammation measured during arthroscopy [196].
IL-21 is highly produced in the synovial fluid of RA patients
compared to paired serum specimens as well as healthy
control sera.The increased levels of IL-21 correlate with those
of IL-17 [202] and an association between levels of IL-21 and
Th17 cells responses in the RA synovium was shown [202].
Similar increased serum levels of many cytokines were
indeed found in other rheumatic diseases: notably PSA [203–
205], SLE [206, 207], AS [208–210], and scleroderma [211, 212]
(IL-1, IL-6, IL-7, IL-8, IL-10, IL-12, IL-16, IL-17, IL-18, and
IFN-gamma, TGF-beta, or TNF-alpha, as well as IL-1RA
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and sIL-2R or leptin) suggesting that such rises may reflect
inflammation rather than being disease specific. Therefore,
the biomarker value of either one of the cytokines, or a
combination of them, will likely depend on whether their
disease specificity can be verified.
3.3. Cytokines as Diagnostic Biomarkers for RA. The early
diagnosis of RA is critical, as it has been demonstrated that
a therapeutic window of opportunity is available very early
in the development of RA, when disease can be stopped
efficiently, preventing structural and functional damage and
leading to remission if treated. In face of such a need,
clinical diagnosis remains difficult. At the (very) early stage,
inflammatory arthritis often has an atypical presentationwith
progression towards RA that can vary in speed. Autoantibod-
ies (RF and ACPA) are useful in RA diagnosis as recently
recognised by their inclusion in the new diagnostic EULAR
2010 criteria. However, they both lack sensitivity in early
disease (<50%) [213] even if ACPA specificity is quite high
(over 95%) [214].
The ideal RA diagnostic biomarker should therefore
be characterised by high specificity and sensitivity, both
close to 100%. An ideal biomarker should also detect the
presence of RA at early stages. Few, if any, biomarker testing
systems achieve these levels of sensitivity and specificity
although this can be approached by improvement of the
assays. In advanced disease (i.e., fully developed RA), bio-
logical differences between healthy and disease states are
easily detected. In contrast, in early disease, the biological
distinctions between healthy and disease states or alternative
diagnosis are oftenmore subtle, and clear differentiation even
for a gold standard becomesmore challenging.Therefore, the
evaluation of a candidate diagnostic biomarker requires an
infallible diagnosis to be established which in RA remains
difficult [215].
Cytokines and other soluble factors are prime candi-
dates for diagnostic biomarkers. Several studies investigated
their expression using variable methods (ELISA, multiplex
assays, or gene expression) and material (tissue and body
fluids). However, few studies actually compared very early
inflammatory arthritis with differential outcome and still
use healthy individuals or established disease patients as
controls. Cytokines detected in joints were not different in
12- month disease duration compared to more advanced RA
[216]; however, these findings remain to be established in
very early disease. Even if right and left RA knee showed
similar profiles (IL-6, IL-8, IL-10, and IFN-gamma, high
expression of IL-1beta, TNF-alpha, and TGF-beta, low levels
of IL-2 and GM-CSF, and no detectable IL-4 or IL-5) [217],
the same pattern was observed in other diseases such as
seronegative spondyloarthropathy or OAwith different levels
of expression.
Using Luminex technology with the blocking of het-
erophilic antibody, increased levels of TNF-alpha, IL-1beta,
IL-6, IL-12P40, IL-13, and several chemokines (CXCL10,
CCL11, CCL2, and IL-8) were observed in sera from RA
patients with <6-month symptom duration compared to HC
[23]. The profile was specific to RA and not reproduced in
established AS or SpA but was not investigated in patients
with early inflammatory symptoms who did not progress
towards RA.The profile was also restricted to ACPA-positive
patients suggesting increased inflammation associated with
autoreactivity. In addition, ACPA was closely related to RF
in this study (titres were directly correlated), questioning
the efficiency of the RF-blocking methodology used as most
cytokine levels were also related to ACPA levels.
In a similar study [158] comparing already diagnosed
RA patients of less than 6-month symptom duration with
established AS and PsA, a multiplex biomarker platform
(combining cytokines, bone turnover markers, metallopro-
teinases, inflammatory markers, and several citrullinated
epitopes) established a signature again including cytokines
such as TNF-alpha, IL-1alpha and beta, IL-6, IL-12p40, IL-15,
IL-17, GM-CSF, and eotaxin. However, most were also present
in AS and PsA (TNF-alpha, IL-1beta, IL-6, IL-17, and eotaxin)
and otherswere associatedwith autoantibody positive disease
(IL-1alpha, IL-12p70, and IL-15).
Studies truly investigating early diseases and the value
of cytokines as diagnostic biomarkers in a predictive man-
ner are few. SF from early inflammatory arthritis patients
before diagnosis established that patients with persistent
symptoms on development of RA showed increase in Th2
cytokines (IL-4 and IL-13) but not Th1 (IFN-gamma) [218].
IL-17 was also increased however only in established RA
[218]. In individuals who donated serum samples and later
developedRA, amultiplex study showed significant increased
levels of cytokines related to T cell activation (IL-2, IL-
6), inflammation (IL-1beta, IL-1RA, and TNF-alpha), Th1
(IL-12 and IFN-gamma), Th2 (IL-4, IL-13, and eotaxin),
and immune regulation (IL-10), while chemokines, stromal
cell-derived cytokines, and angiogenic-related markers were
elevated in patients after the development of RA rather
than in individuals before the onset of RA [219]. Levels
were particularly increased inACPA-positive andRF-positive
individuals. However, in all three studies, every cytokine and
chemokine tested were increased (even if not significantly)
and again particularly inACPA/RF-positive patients, whereas
other studies demonstrated reduction (i.e., IL-2 and IL-7).
Therefore, technical issues related to heterophilic antibody
interference may have to be considered when interpreting
these data. A similar preclinical RA study [220] showed no
detectable cytokine more than 5 years before RA onset, but
during the 5-year interval before diagnosis, increased levels
were associated with an increased likelihood of the risk of
developing RA (IL-1 alpha, IL-1beta, IL-1RA, IL-4, IL-10,
TNF-alpha, and soluble TNF-RI).
In established RA as well as in patients with less than 24-
month symptom duration, reduced levels of circulating IL-7
have been reported [177, 196]. IL-7 is a pleiotropic cytokine
regulating peripheral T cell homeostasis, notably in RA [177,
221, 222]. However, IL-7 is highly expressed in the joints
of RA patients [196, 197, 223, 224], and such discrepancies
between low systemic levels and high expression at disease
site have also been reported in systemic sclerosis [225] and
recently in ulcerative colitis and Crohn’s disease [226, 227]. A
cohort of 250 sera from patients with very early symptoms
suggesting a possible evolution towards RA (less than 6-
month duration and 5-year follow-up) designed to discover
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diagnostic biomarkers demonstrated the potential of IL-7 as
a biomarker [2].
3.4. Cytokines asMarkers for Treatment Selection andResponse
toTherapy. Biological therapies (cytokine blockade or recep-
tor antagonism) nowadays appear very effective in chronic
inflammatory conditions such as RA, however, in a limited
number of patients, with up to 40% nonresponse. Consider-
ing the cost of such therapies, biomarker prediction response
and allowing for selection of the most appropriate biological
treatment would have considerable impact. Most authorities
recommend starting therapy with biologics after the failure
to respond to at least one disease-modifying agent in RA.
However, due to the limited number of studies, there is little
guidance aboutwhich biological agent to select although anti-
TNF remains the most commonly used.
RA patients not responding to anti-TNF showed higher
synovial fluid IL-6 at baseline amongst elevated levels of IL-
1beta, IL-1RA, IL-2, IL-4, IL-8, IL-10, IL-17, IFN-gamma, G-
CSF, GM-CSF, and TNF-alpha. In contrast, responders had
elevated IL-2 and G-CSF. In plasma, however, levels were not
significantly predicting response, and IL-6 levels decreased
posttreatment. In this study, SF cytokine clustering revealed 6
groups of patients with possibly underlying different cellular
pathologies, and IL-6, IL-2, and G-CSF in SF may be useful
in predicting response to anti-TNF [228]. Recently, we also
showed that serum IL-6 was significantly higher at baseline
in rituximab nonresponders and that a significant reduction
followed treatment in responders only despite adequate B
cell depletion in nonresponders [229]. Multivariate logistic
regression analysis of synovial cytokine expression showed
that TNF at baseline could only explain ∼10–15% of the
variance in response to TNF blockade [230], suggesting that
TNF expression itself would have a limited role in relation to
personalised health care. Synovial tissue analysis associated
absence of sign of improvement with increased TNF and
MMP-3 expression [231, 232]. In contrast, another study
showed response to be associatedwith higher TNFbioactivity
in the blood [233], which is more convenient for personalised
medicine.
To date, several studies using blood have used gene
expression rather than ELISA. CCL4, IL-8, and IL-1beta dis-
criminated between responders and nonresponders to anti-
TNF [234]. Several gene signatures have been published so
far (some including IL-8, IL-2R) [235–238] with a sensitivity
of 90% and a specificity of 70% [237] and 94.4% sensitivity
and 85.7% specificity for the response to anti-TNF treatment
[238]. Response to anti-TNF (etanercept) was associated
with reduced levels of IL-6 and increased IL-23 and IL-32
posttreatment while there was no change in nonresponders;
however, no baseline level had predictive value [239].
Recently, several interferon signalling related signatures
have emerged as potential biomarkers of response to biolog-
ical therapies [240–242] as well as for the progression of “at
risk” individuals to symptomatic arthritis [243]. Such signa-
tures are interesting as theymost likely reflect an immunolog-
ical status that is favourable to responding or not to therapy,
although they are not really linked to the presence/absence of
interferon. Indeed, these signatures combined different sets of
intracellular signalling factors and transcriptional regulators
(between 8 and 15 markers) and are measured through gene
expression (using mostly qPCR).
4. Conclusion
Assays measuring known diagnostic biomarkers are com-
monly used in clinical practice. In fact, it has been reported
that about 70% of the decisions made by physicians are based
on the results provided by those tests [244]. However, the
implementation of novel biomarkers into clinical practice
proves to be a long and challenging process, which includes
convincing physicians.The assessment of the impact of using
the biomarker on general health is an essential step to
guarantee the uptake of the biomarker into clinical practice
and to further optimise its use. This area of research is likely
to become increasingly important as more biomarkers enter
clinical practice [245]. Given the complexity and heteroge-
neous nature of RA, it is unlikely that a single cytokine
may provide sufficient discrimination.Many reliable cytokine
assays are nowadays available with multiplex formats taking
the lead (although this may not be an appropriate solution
in RA due to RF interferences). These have established
clinical utility for other diseases and purposes and should
be easily (technically) transferable to rheumatology, although
the exact performance characterization and quality assurance
for the specific cytokines of interest in RA may need to be
established. At present, limitation in RA lies more in the
disease related complexity of networks, the elucidation of the
respective role, and the redundant effect that one cytokine
may have with another.
Finally, multiple biomarker signatures potentially using
genetic as well as proteomic markers may represent a more
realistic approach for the future of personalised medicine
in RA. Such multifactorial analysis may potentially reveal
patterns rather than individual biomarkers. As such, it is
interesting that IL-7 alone was able to predict diagnostic at
very early disease stage, whereas more complex combination
of markers may be needed to predict response to therapy
and define subsets of patients with more advanced and
heterogonous disease.
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